PO:16:227 | Anifrolumab for Systemic Lupus Erythematosus: Preliminary Safety and Efficacy Findings from the Italian Experience: Paola Bizioli1|2, Chiara Orlandi1|2, Claudia Barison1|2, Cesare Tomasi3, Alessia Caproli1, Silvia Piantoni1|2, Simona Signorini4, Emirena Garrafa4, Cecilia Nalli1, Micol Frassi1, Ilaria Cavazzana1|2, Micaela Fredi1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia, Italy; 3Department of Clinical and Experimental Sciences, University of Brescia, Italy; 4Laboratory of Clinical Chemistry, Department of Molecular and Translational Medicine, University of Brescia, Italy. Reumatismo [Internet]. 2026 Mar. 18 [cited 2026 Apr. 30];77(s1). Available from: https://www.reumatismo.org/reuma/article/view/2333